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Allogeneic hematopoietic stem cell 
transplantation in patients with diffuse large B 
cell lymphoma relapsed after autologous stem 
cell transplantation: A GITMO study 
Abstract 
Patients who relapse after an autologous hematopoietic stem cell transplantation (SCT) have a very 
poor prognosis. We have retrospectively analyzed diffuse large B cell lymphoma patients who 
underwent an allo-SCT after an auto-SCT relapse reported in the Gruppo Italiano Trapianto di 
Midollo Osseo (GITMO) database. From 1995 to 2008, 3449 autologous transplants were reported 
in the GITMO database. Eight hundred eighty-four patients relapsed or progressed after transplant; 
165 patients, 19% of the relapsed patients, were treated with allo-transplant. The stem cell donor 
was related to the patient in 108 cases. A reduced intensity conditioning regimen was used in 116. 
After allo-SCT, 72 patients (43%) obtained a complete response and 9 obtained a partial response 
with an overall response rate of 49%; 84 patients (51%) experienced rapid progression of disease. 
Ninety-one patients died, 45 due to disease and 46 due to treatment-related mortality. Acute graft-
versus-host disease was recorded in 57 patients and a chronic GvHD in 38 patients. With a median 
follow-up of 24 months (2–144) after allo, overall survival (OS) was 39%, and after a median of 
21 months (2–138) after allo, progression-free survival (PFS) was 32%. Multivariate analysis 
indicated that the only factors affecting OS were status at allo-SCT, and those affecting PFS were 
status at allo-SCT and stem cell donor. This retrospective analysis shows that about one-fifth of 
patients with diffuse large B cell lymphoma who experience relapse after autologous transplantation 
may be treated with allogeneic transplantation. Moreover, the only parameter affecting either OS or 
PFS was the response status at the time of allo-SCT. 
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This study was presented, in part, at the EBMT Annual Meeting, Vienna on March 21–24, 2010. 
Introduction 
High-dose chemotherapy with autologous hematopoietic stem cell transplantation (auto-HSCT) has 
an established role in the treatment of patients with first relapsed aggressive lymphoma [1–3]. The 
use of auto-HSCT in the first-line treatment of aggressive lymphoma is still a matter of debate, and 
its use is restricted to clinical trials. The outcome and prognosis of relapsed or progressed after 
auto-HSCT in patients is poor, with an overall survival of less than 11% at 1 year [4]. Conventional 
dose salvage chemotherapy can induce disease remission in a small proportion of patients, but it is 
not long lasting. A second auto-HSCT is sometimes performed and results are disappointing, but it 
is most likely to benefit patients in prolonged remission after the initial auto-HSCT [5, 6]. 
Allogeneic hematopoietic stem cell transplantation (allo-SCT) could be considered a therapeutic 
option for these high-risk patients. The postulated advantages of an allo-SCT include the use of a 
tumor-free graft and immune-mediated graft-versus-lymphoma effects [7, 8], but the survival 
benefit is usually offset by a nonrelapse mortality rate. As seen with other transplant indications, 
any reduction in relapse achieved with allo-SCT is offset by mortality attributable to the treatment 
itself [9–13]. This problem has resulted in the exclusion of older patients and those with 
comorbidities. Similarly, even in younger patients who have relapsed after an autologous transplant, 
allogeneic transplantation with myeloablative conditioning has been associated with a prohibitive 
risk of nonrelapse mortality [14–16]. The development of less intensive but highly 
immunosuppressive conditioning regimens that rely on possible graft-versus-tumor effects have 
increased the number of patients who are candidates for allografts [17–19], including those who 
relapse after auto-HSCT as reported in the recent paper by van Kampen et al [20]. To assess the 
clinical results of an allo-SCT in diffuse large B cell lymphoma (DLBCL) patients, whose disease 
has failed a prior autologous transplantation, we analyzed 165 patients with diagnosis of DLBCL 
whose data were reported to the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) registry. 
Patients and methods 
We have analyzed the GITMO database serching for DLBCL patients treated with autologous 
transplant from 1995 to 2008 in 93 Italian transplant units, and we have selected those patients who 
relapsed after auto-HSCT and treated with allo-SCT. We have studied 165 patients with a diagnosis 
of DLBCL undergoing allo-SCT, after autologous transplantation relapse, in 48 Italian centers. The 
analysis was based on the allogeneic transplantation GITMO registry data. The procedures followed 
were in accordance with the ethical standards of the Istitutional Committee on Human 
Experimentation and GITMO, as well as with the Declaration of Helsinki. All clinical variables 
were analyzed at the time of allo-transplant, and all patients fulfilled the minimal essential data for 
analysis including sex, age, chemosensitivity, disease status at allo-transplant, conditioning 
regimen, stem cell source, stem cell donor, and follow-up data. Various other data were also 
collected: therapy performed between auto-HSCT and response to allogeneic transplant, allo-
transplant relapse, type of therapy after allo-transplant relapse, response to salvage therapy, causes 
of death, and acute and chronic graft-versus-host disease. The anti-CD20 antibody (rituximab) was 
used in association with first-line chemotherapy in all patients diagnosed after 2002 and in 
association with salvage therapy in patients relapsed after 2002 because from that year, the antibody 
was licensed for the use in DLBCL by the Italian authorities. The choice of conditioning was 
decided by the treating physicians who followed the center’s protocols. All patients were restaged 
by using total body computed tomography, and in patients with bone marrow infiltration, biopsy 
was repeated. Nonrelapse mortality was defined as time to deaths without relapse/recurrence. Donor 
lymphocyte infusion (DLI) was performed according to the following guidelines: Transplant from 
an HLA identical sibling: first infusion 5 × 106 CD3/kg, second 1 × 107 CD3/kg, third 5 × 107 
CD3/kg, and fourth 1 × 108 CD3/kg. Transplant from unrelated donor: first infusion 5 × 105 CD3/kg, 
second 1 × 106 CD3/kg, third 5 × 106 CD3/Kg, and fourth 1 × 107 CD3/kg. 
Statistical analysis 
All patients included in the study were considered for statistical analysis. Overall survival (OS) was 
calculated from allo-transplantation to death for any cause or last contact, while progression-free 
survival (PFS) was calculated from allo-transplantation to progression, relapse, and death for any 
causes or last follow-up. OS and PFS were calculated using the Kaplan–Meier product-limit 
estimate. Nonrelapse mortality was evaluated with a competing risks analysis. The log rank test was 
used to assess the significance of differences for each prognostic factor in the univariate analysis. 
All factors reported in the database were analyzed, and those showing a significant impact, or a 
trend towards an impact in the univariate analysis (p  < 0.15), were entered into the multivariate 
analysis. Multivariate analysis was performed using the Cox proportional hazards regression model, 
utilizing a stepwise conditional backward method. Data were analyzed using the Statistical Package 
for Social Science version 13.0 [21], except for the cumulative incidence analyses that were 
performed with the NCSS97 [22]. The limit of significance for all the analyses was defined as 
p = 0.05. 
Results 
Our analysis of the GITMO database from 1995 to 2008 in 93 Italian transplant units indicated that 3449 
patients were treated with autologous stem cell transplantation. After a median observation period of 
12 months, 293 patients were lost to the follow-up, and 884 patients relapsed or progressed after 
autologous transplant. One hundred sixty-five (19%) of these 884 patients were then treated with allo-
transplant. The last follow-up was in July 2009. Table 1 shows the patients’ characteristics. Patients’ median 
age at auto-HSCT was 41 years (15–62), and median age at allo-SCT was 43 years (16–65). One hundred ten 
patients (67%) responded to any type of salvage therapy used and 55 did not. The disease status at allo-SCT 
was complete remission (CR) in 53 patients (32%), partial remission (PR) in 38 (23%), and stable disease and 
progressive disease in 74 patients (45%). 
Table 1 Patients’ characteristics 
 
 
 
Patients, disease, and transplant characteristics 
The median interval between auto-HSCT and allo-SCT was 13 months (range 3–128 months). One hundred 
eight patients (65%) received transplants from an HLA-identical sibling and 57 (35%) from an unrelated 
donor which were HLA I class locus A and B identical with low resolution and DRB1 (high resolution) 6/6 
matched. The conditioning regimen was myeloablative in 49 patients (30%) and nonmyeloablative or with 
reduced intensity conditioning (RIC) in 116 (70%). The conditioning regimen was reported in 73 RIC patients 
(19 with TBI, 26 with fludarabin containing regimen, 24 with tyotepa containing regimen, and 4 with 
busulfan containing regimen), and in 34 myeloablative conditioning therapy patients (11 with TBI, 6 with 
busulfan containing regimen, and 17 with tyothepa containing regimen). The two groups of patients were 
not comparable for complete remission status at allo-SCT and chemosensitive disease which was higher in 
the reduced intensity conditioning group (Table 2). Graft-versus-host disease (GvHD) prophylaxis was 
performed according to single institution practice. In particular, it was possible to collect the data in 78 
patients, 52 treated with nonmyeloablative conditioning and 26 with myeloablative conditioning. In 
nonmyeloablative conditioning, 30 patients were treated with cyclosporine and methotrexate; 5 with 
cyclosporine, methotrexate, and ATG; 5 with cyclosporine; 4 with cyclosporine and mycophenolate; 3 with 
cyclosporine, mycophenolate, and anti-CD52; and 5 other. In patients with myeloablative regimen, 19 
patients were treated with cyclosporine and methotrexate, 3 with cyclosporine, and 4 other. An acute 
GvHD was registered in 60 patients (36%): grade 1 in 18 patients, grade 2 in 27 patients, grade 3 in 7 
patients, grade 4 in 7 patients, and grade 5 in 1 patient. The data in 14 patients were not available. A 
chronic GvHD was observed in 40 patients (24%): grade 1 in 25 patients and grade 2 in 15 patients. The 
data in 48 patients were not available. More than two-thirds of allo-SCT (147) were performed in the years 
between 2002 and 2008 (post rituximab era), whereas the remaining procedures were performed in the 
previous years (1995–2001). The response to allo-SCT was not evaluable in 55 patients, and they were 
considered nonresponders; it was evaluable in 110 patients and was completed in 72 patients (65%) and 
partial in 9 (8%). Considering all patients, the overall response rate was 49%. Twenty-nine patients were 
nonresponders or presented a rapid progression of disease. Thirty-nine out of 112 (28%) patients, not in 
complete remission at the time of allo-SCT, achieved a complete remission after allo-transplant. 
Table 2 
Patients’ characteristics according to conditioning regimen (reduced intensity conditioning and 
myeloablative regimen) 
  
Myeloablative (49 
patients) 
Nonmyeloablative (116 
patients) 
p 
value 
Median age in years 
(range) 
38 (16–61) 46 (19–65)   
Male 25 (51%) 65 (56%)   
Female 24 (49%) 51 (44%) n.s. 
Status at allo-HSCT 
Complete remission 10 (21%) 45 (39%)   
Partial remission 9 (18%) 29 (25%)   
Nonresponder 30 (61%) 42 (36%) 0.01 
Sensitivity to treatment 
Chemosensitive relapse 25 (51%) 85 (73%)   
Chemorefractory relapse 24 (49%) 31 (27%) 0.003 
Donor 
Sibling HLA-identical 32 (65%) 76 (651%)   
Unrelated 17(35%) 40 (35%) n.s. 
Stem cell source 
Bone marrow 9 (18%) 17 (15%)   
Peripheral blood 38 (78%) 96 (82%)   
Both 1 (2%) 1 (1%)   
Cord blood 1 (2%) 2 (2%) n.s. 
Response post allo-HSCT n = 30 patients n = 80 patients   
  
Myeloablative (49 
patients) 
Nonmyeloablative (116 
patients) 
p 
value 
CR 17 (57%) 55 (69%)   
PR 5 (17%) 4 (6%)   
Progressive disease 8 (26%) 21 (25%) n.s. 
Graft-versus-host disease n = 30 patients n = 65 patients   
Acute GVH 20 (67%) 37 (57%) n.s. 
Chronic GVH 10 (33%) 28 (43%) n.s. 
Outcome 
Alive 18 (37%) 56 (48%)   
Dead 31 (63%) 60 (52%) n.s. 
n.s. not significant 
Survival outcomes 
The median period of observation after allo-SCT for 79 patients who remained alive was 39 months (range 
1–144 months): 15 (20%) were alive with lymphoma and 59 (80%) without evidence of lymphoma at last 
follow-up. Ninety-one patients died: 45 from progressive disease, 33 were due to toxicity other than GvHD, 
and 13 from acute GvHD. The nonrelapse mortality rate was 28%, and mortality associated with progressive 
disease was 25%. The cumulative incidence for nonrelapse mortality was significantly associated with 
alternative donor versus sibling donor (32% versus 19%, p = 0.05) (Fig. 1a). Partial response was significantly 
associated with progressive disease posttransplant versus complete remission posttransplant (30% and 
10% versus 9%, p = 0.03) (Fig. 1b). Mortality was significantly associated with the disease status at 
transplant (PR and no response versus CR, p = 0.001), chemorefractory disease (p = 0.05), alternative donor 
(p = 0.03), and response posttransplant (partial remission and nonresponder versus complete remission, p  
< 0.001). There were no significant differences in OS, regardless of whether relapse was more or less than 
1 year post auto-HSCT, with 25 and 49 patients alive and 22 and 69 dead, respectively (p = 0.9). A better PFS 
was observed in patients who relapsed 1 year after auto-HSCT (p  = 0.02). No differences were observed 
concerning the conditioning regimen nor when considering the two periods of treatment before and after 
2002. 
 Fig. 1 Treatment related mortality (TRM) or nonrelapse mortality (NRM) according to a donor and 
b status posttransplant 
 
The Kaplan–Meier estimates of OS after transplantation were 55% at 1 year, 42% at 3 years, and 39% at 
5 years with 81, 41, and 22 patients at risk, respectively (Fig. 2) (IC 95%, 36–52). Progression free survival 
after transplantation was 48% at 1 year, 34% at 3 years, and 31% at 5 years with 81, 41, and 22 patients at 
risk, respectively (Fig. 3) (IC 95%, 25–43). 
 
 
 
Fig. 2 After a median follow-up of 24 months (range 2-144 months) the Overall Survival was 39% 
(IC 95% 31-48) 
 
 
Fig. 3 
After a median follow-up of 21 months (range 2-138 months) the Progression Free Survival was 
32% (IC 95% 23-41) 
According to univariate analysis, the parameters significantly associated with a better OS were CR before 
patients who underwent allo-SCT, while in complete remission (p = 0.001), they were chemosensitive 
relapse (p = 0.02). According to multivariate analysis, the best survival was associated only with disease 
status at allo-SCT (Fig. 4). 
 
 
Fig. 4 
Overall survival according to status pre allo-transplant (CR complete remission, PR partial 
remission, NR nonresponders) 
 
 
According to univariate analysis, the parameters significantly associated with a better PFS were CR before 
allo-SCT (p = 0.0008), chemosensitive relapse (p = 0.006), and sibling donor (p  = 0.04). According to 
multivariate analysis, the best progression-free survival was associated with disease status at allo-SCT 
(Fig. 5) and sibling donor. 
 
 
 
 
Fig. 5 
Progression-free survival according to status pre allo-transplant (CR complete remission, PR partial 
remission, NR nonresponders) 
Therapy for relapse after allo-SCT 
One hundred ten patients (67%) relapsed or progressed after allo-SCT and 55 did not. In 66 out of 
110 patients (60%), it was not possible to apply any therapy, due to the aggressiveness and rapid 
progression of the disease. Therapy was possible in 44 patients; donor lymphocyte infusion was 
performed in 26 patients, a second allo-SCT in 6 patients, and chemoimmunotherapy or 
radiotherapy in 12 patients. Twenty out of 44 patients treated after allo-SCT relapse obtained a new 
response, with 12 patients obtaining a new complete response. Six out of 26 patients were treated 
with DLI (23%), 3 out of 6 (50%) with a second allo-SCT, 3 out of 12 (25%) with 
chemoimmunotherapy or radiotherapy. Thirteen patients (29.5%) were alive without evidence of 
disease after a median period of 12 months 
Discussion 
In this study, we have analyzed the largest group to date of allo-SCT treatment for patients with 
DLBCL who have relapsed after high-dose therapy and auto-HSCT. This large cohort of patients 
provides consolidated information that may help clinicians in managing these high-risk patients. 
Moreover, the GITMO database contains a certain number of obligatory fields concerning the 
patients. 
There are also inherent weaknesses in retrospective registry-based studies. Only patients who 
undergo transplantation are reported in the registry of a selected population, and in our experience, 
they represent about 20% of patients relapsed after auto-HSCT. Data submitted from centers may 
be incomplete despite the requirement for consecutive case reporting and the provision of minimal 
essential data. Although high-dose chemotherapy with autologous stem cell support is effective, 
salvage treatment for many patients with relapsed or refractory DLBCL is necessary, and there is a 
significant number in whom the disease will recur and whose outlook is extremely poor [23]. 
Patients treated with a second autologous transplant or with conventional therapy after failed 
autologous transplantation have a very poor prognosis. Vose et al. [4] reviewed the outcomes of 169 
patients who had malignant lymphoma and who relapsed after auto-SCT. With a median follow-up 
of 1 year, 18 (11%) of these 169 patients were alive, off therapy and without evidence of disease 
progression. By contrast in this study, 1-, 3-, and 5-year OS were 55%, 42%, and 39%, respectively. 
Thus, the OS rate of patients included in our study appears to be remarkably higher than that 
reported for patients treated with conventional therapy after auto-SCT relapse. More recently, in the 
paper by van Kampen et al. [20], similar results were reported in a larger number of patients. 
Allo-SCT is increasingly used because it has the potential advantages of a graft-versus-tumor effect 
and a tumor-free graft effect. The role of allogeneic transplantation in relapsed DLBCL is currently 
a field of study with relatively little published data and a lack of consistent findings [6, 14, 16, 24–
26]. The toxicity of myeloablative allogeneic transplantation is high, with most groups reporting 
nonrelapse mortality rates of more than 50%, with the exception of a recent paper by the 
International Bone Marrow Transplant Registry group that reports a nonrelapse mortality rate of 
22% [8, 26–31]. 
In the present study, nonrelapse mortality was 28%. Approximately a quarter of our patients died 
from progression of disease after allo-SCT at a mean of 6 months (range 0–45 months). Nonrelapse 
mortality in our study was mainly affected by alternative donor and lack of response after allo-
transplant. In the literature, the reduced intensity conditioning regimen has shown a lower 
nonrelapse mortality making this a viable option for patients usually excluded from the 
conventional allo-SCT [32, 33]. There are few published studies on the outcome of reduced 
intensity conditioning in diffuse large B-cell lymphoma or in aggressive lymphoma [34–39]. For 
patients with relapsed DLBCL, nonrelapse mortality rates with reduced intensity conditioning 
allogeneic transplantation, with few exceptions [36, 40], have been surprisingly high (range 25–
38%) [34, 41, 42]. In our study, although many features were not comparable between 
myeloablative or reduced intensity conditioning regimens (see Table 2), no differences were 
reported in the two groups concerning overall survival and progression-free survival according to 
univariate analysis. In comparison with low-grade lymphoma treated with allo-SCT, the evidence 
supporting a graft-versus-tumor effect in aggressive grade lymphoma is less compelling, and while 
such an effect may exist, its contribution to the prevention of relapse appears to be much less 
substantial. It is possible that with aggressive-grade lymphomas, the slow-acting graft-versus-
lymphoma effect is overridden by the rapidity of growth of the tumor. Many studies report that the 
status at allo-SCT is one of the most important parameters to predict OS and PFS. In our 
experience, almost one-third of patients were in CR at the time of allo-SCT. It should be noted that 
OS and PFS were significantly affected by the CR status at the moment of allo-SCT according to 
multivariate analysis. Clinical observations of patients undergoing myeloablative and 
nonmyeloablative allo-SCT suggest that the graft-versus-tumor effects may be important in 
inducing prolonged remission in patients with lymphoma [15, 43] and that it constitutes one of the 
rationales for considering allogeneic transplantation. No differences were observed in terms of 
overall and progression-free survival, the rate of mortality and progression in patients with acute or 
chronic graft-versus-host disease or those without. This is probably due to the fact that, in our study, 
only 34% and 23% of patients developed an acute or chronic graft-versus-host disease. Several 
previous retrospective registry analyses have similarly failed to demonstrate such an effect [44, 45]. 
Information about outcomes of chemorefractory patients following myeloablative or reduced 
intensity conditioning allo-transplant is limited. Two studies suggest significantly inferior outcomes 
of such patients compared to those with chemosensitive relapse [41, 46]. In a recent paper, Sirvent 
and colleagues [47] concluded that reduced intensity allogeneic transplantation is an attractive 
option that prolongs survival in high-risk diffuse large B-cell lymphoma patients. In our study, it is 
clear that patients with chemosensitive relapse show a better overall and progression-free survival 
in comparison to chemorefractory patients. Nevertheless, it is important to note that overall survival 
was 27% in chemorefractory patients, showing the existence of an active immunological effect of 
allogeneic transplantation. Moreover, patients who relapsed after allo-SCT obtained a new response 
with immunological therapy (second allo-transplant or DLI), assuming the emergence of graft-
versus-lymphoma immune responses. 
In summary, it is apparent from the present study that about one-fifth of the patients with DLBCL 
who experience relapse after autologous transplantation may be treated with allogeneic 
transplantation. Those who respond to salvage therapy and who have HLA identical siblings have a 
relatively good 3-year overall and progression-free survival. 
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